CYANOTECH Posts Consistent Loss Per Share Amidst Debt Restructuring
Ticker: CYAND · Form: 10-K · Filed: Jun 20, 2025 · CIK: 768408
| Field | Detail |
|---|---|
| Company | Cyanotech Corp (CYAND) |
| Form Type | 10-K |
| Filed Date | Jun 20, 2025 |
| Risk Level | high |
| Sentiment | bearish |
Sentiment: bearish
Topics: Medicinal Chemicals, Botanical Products, Net Loss, Debt Restructuring, 10-K Filing, Small Cap, Hawaii
Related Tickers: CYAND
TL;DR
**CYAND is stuck in a rut with persistent losses and debt, making it a risky bet for any growth-focused investor.**
AI Summary
CYANOTECH CORP reported a net loss for the fiscal year ending March 31, 2025, with a diluted loss per share of $0.02, consistent with the prior year's loss per share of $0.02. The company's common stock outstanding remained at 7,199,908 shares for both 2025 and 2024. There were no significant changes in revenue or net income figures provided in the excerpt, indicating a stable but unprofitable financial performance. Key business changes include the conversion of a revolving credit facility into a term loan with First Foundation Bank on October 13, 2023, and the existence of a term loan agreement maturing on August 14, 2032. The company also maintains an unsecured subordinated loan, the Skywords Note, which was established on April 30, 2019. Strategic outlook remains focused on managing existing debt obligations and maintaining operations, as evidenced by the consistent share count and ongoing loan agreements.
Why It Matters
CYANOTECH's consistent net loss per share of $0.02 for both 2025 and 2024 signals ongoing operational challenges, which could impact investor confidence and future growth prospects in the medicinal chemicals and botanical products sector. The conversion of a revolving credit facility to a term loan with First Foundation Bank on October 13, 2023, indicates a strategic shift in debt management, potentially affecting the company's liquidity and financial flexibility. For employees, sustained losses could raise concerns about job security and future investment in the business. In a competitive market, the inability to achieve profitability may hinder CYANOTECH's capacity to innovate and expand, potentially losing ground to more financially robust competitors.
Risk Assessment
Risk Level: high — The company reported a diluted loss per share of $0.02 for both the fiscal years ending March 31, 2025, and March 31, 2024, indicating a lack of profitability. Furthermore, the presence of an unsecured subordinated loan (Skywords Note from April 30, 2019) and a term loan agreement maturing in 2032 suggests significant long-term debt obligations that could strain future cash flows.
Analyst Insight
Investors should exercise extreme caution and thoroughly review the full 10-K for detailed financial statements and operational specifics before considering any investment in CYAND, given the consistent losses and existing debt structure. A deeper dive into revenue trends and cash flow from operations is critical to assess viability.
Key Numbers
- $0.02 — Diluted Loss Per Share (Consistent for fiscal years 2025 and 2024)
- 7,199,908 — Common Stock Outstanding (Consistent for fiscal years 2025 and 2024)
- 2025-03-31 — Fiscal Year End (Reporting period for the 10-K)
- 2023-10-13 — Term Loan Conversion Date (Date revolving credit facility converted to term loan with First Foundation Bank)
- 2032-08-14 — Term Loan Maturity Date (Maturity date for a significant term loan agreement)
- 2019-04-30 — Skywords Note Establishment Date (Date the unsecured subordinated loan was established)
Key Players & Entities
- CYANOTECH CORP (company) — filer of the 10-K
- First Foundation Bank (company) — lender for term loan
- Michael Davis (person) — Chairman of the Board of Directors
- Skywords Note (company) — unsecured subordinated loan
- 03 Life Sciences (company) — organization name
- Nevada (regulator) — state of incorporation
- SEC (regulator) — regulator for 10-K filing
- Bloomberg (company) — publisher of analysis
FAQ
What were CYANOTECH CORP's net sales for the fiscal year ending March 31, 2025?
The provided excerpt does not contain specific net sales figures for the fiscal year ending March 31, 2025. It only mentions that net sales are attributed to countries based on customer location.
How has CYANOTECH CORP's diluted loss per share changed from 2024 to 2025?
CYANOTECH CORP's diluted loss per share remained consistent at $0.02 for both the fiscal year ending March 31, 2025, and the fiscal year ending March 31, 2024.
Who is the Chairman of CYANOTECH CORP's Board of Directors?
Michael Davis is the Chairman of CYANOTECH CORP's Board of Directors, as stated in the filing.
What is the maturity date of CYANOTECH CORP's main term loan agreement?
CYANOTECH CORP has a term loan agreement maturing on August 14, 2032, as detailed in the filing.
When was the Skywords Note established for CYANOTECH CORP?
The Skywords Note, an unsecured subordinated loan for CYANOTECH CORP, was established on April 30, 2019.
What is CYANOTECH CORP's state of incorporation?
CYANOTECH CORP is incorporated in the state of Nevada.
How many shares of common stock did CYANOTECH CORP have outstanding as of March 31, 2025?
As of March 31, 2025, CYANOTECH CORP had 7,199,908 shares of common stock outstanding, which was consistent with the prior year.
What is the primary business of CYANOTECH CORP?
CYANOTECH CORP operates in the Medicinal Chemicals & Botanical Products industry, classified under SIC code 2833.
What is the risk associated with CYANOTECH CORP's financial performance?
The risk is high due to consistent diluted losses per share of $0.02 for both 2025 and 2024, coupled with significant long-term debt obligations like the term loan maturing in 2032 and the Skywords Note.
When was CYANOTECH CORP's 10-K filing submitted to the SEC?
CYANOTECH CORP's 10-K filing was submitted to the SEC on June 20, 2025.
Risk Factors
- Consistent Net Loss [medium — financial]: Cyanotech Corp. reported a net loss for the fiscal year ending March 31, 2025, with a diluted loss per share of $0.02. This performance is consistent with the prior year's loss per share of $0.02, indicating a lack of profitability improvement.
- Debt Obligations [medium — financial]: The company has a term loan agreement maturing on August 14, 2032, and an unsecured subordinated loan, the Skywords Note, established on April 30, 2019. Managing these debt obligations is a key focus, suggesting potential financial strain.
- Reliance on Existing Operations [low — operational]: The company's strategic outlook is focused on managing existing debt and maintaining operations, as evidenced by the consistent share count and ongoing loan agreements. This suggests a lack of aggressive growth strategies or new initiatives.
Industry Context
Cyanotech Corp. operates in the medicinal chemicals and botanical products sector (SIC 2833). This industry involves the development and production of health-related products derived from natural sources. The sector can be competitive, with companies focusing on research, quality control, and market access for specialized ingredients and supplements.
Regulatory Implications
As a producer of medicinal chemicals and botanical products, Cyanotech Corp. is subject to regulations concerning product safety, efficacy, and manufacturing practices. Compliance with bodies like the FDA (if applicable to their specific products) is crucial. Any changes in regulatory standards or enforcement could impact operations and market access.
What Investors Should Do
- Monitor Debt Repayment Capacity
- Analyze Revenue Drivers
- Evaluate Strategic Growth Initiatives
Key Dates
- 2025-03-31: Fiscal Year End — This is the reporting period for the 10-K filing, providing the latest financial snapshot.
- 2023-10-13: Revolving Credit Facility Conversion — The company converted its revolving credit facility into a term loan with First Foundation Bank, indicating a shift in financing structure.
- 2032-08-14: Term Loan Maturity — This is the maturity date for a significant term loan agreement, highlighting a long-term debt obligation.
- 2019-04-30: Skywords Note Establishment — This marks the establishment of an unsecured subordinated loan, adding to the company's debt structure.
Glossary
- Diluted Loss Per Share
- The net loss per share after accounting for all potential dilutive common shares, such as stock options and convertible securities. (Indicates the company's profitability on a per-share basis, even when in a loss-making position.)
- Common Stock Outstanding
- The total number of shares of common stock that have been issued and are held by investors. (Represents the ownership structure and is used in EPS calculations.)
- Revolving Credit Facility
- A type of credit line that allows a company to borrow, repay, and re-borrow funds up to a certain limit over a specified period. (Represents a flexible source of short-term financing that was converted to a term loan.)
- Term Loan
- A loan from a bank or other financial institution, typically repaid over a fixed period with a specified interest rate. (A significant debt instrument for the company with a defined maturity date.)
- Unsecured Subordinated Loan
- A loan that is not backed by collateral and ranks below other debts in the event of liquidation. (Represents a specific type of debt obligation with potentially higher risk for the lender.)
Year-Over-Year Comparison
Cyanotech Corp.'s fiscal year ending March 31, 2025, shows a continued net loss with a diluted loss per share of $0.02, unchanged from the prior year. The number of common shares outstanding also remained stable at 7,199,908. The conversion of a revolving credit facility to a term loan with First Foundation Bank on October 13, 2023, represents a structural change in debt financing compared to the previous reporting period.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on June 20, 2025 by Michael Davis regarding CYANOTECH CORP (CYAND).